Tucatinib Alternatives Compared
Tucatinib | Palbociclib | Pembrolizumab |
|
---|
Tucatinib | Palbociclib | Pembrolizumab |
|
---|---|---|---|
Prescription only
Prescribed for Colorectal Cancer, Breast Cancer. tucatinib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Breast Cancer - Metastatic, Liposarcoma, Breast Cancer, Breast Cancer - Male. palbociclib may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Bladder Cancer, Breast Cancer, Cervical Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
|
More about Tucatinib | More about Palbociclib | More about Pembrolizumab | |
Ratings & Reviews | |||
Be the first to share your experience with this drug. |
Palbociclib has an average rating of 6.9 out of 10 from a total of 98 ratings on Drugs.com. 63% of reviewers reported a positive effect, while 29% reported a negative effect. |
Pembrolizumab has an average rating of 4.6 out of 10 from a total of 233 ratings on Drugs.com. 38% of reviewers reported a positive effect, while 54% reported a negative effect. |
|
Drug Class | |||
Side Effects | |||
See also: tucatinib side effects in more detail. |
See also: palbociclib side effects in more detail. |
See also: pembrolizumab side effects in more detail. |
|
Generic Availability | |||
N/A |
N/A |
N/A |
|
Pricing and Coupons * Prices are without insurance | |||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
Dosage Forms Available | |||
N/A |
N/A |
N/A |
|
Brand Names | |||
Tukysa | Ibrance | Keytruda | |
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | |||
8.5 hours |
29 hours |
624 hours |
|
CSA Schedule ** View glossary of terms | |||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
Pregnancy Category | |||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
|
Drug Interactions | |||
A total of 493 drugs are known to interact with tucatinib:
|
A total of 459 drugs are known to interact with palbociclib:
|
A total of 16 drugs are known to interact with pembrolizumab:
|
|
Alcohol/Food/Lifestyle Interactions | |||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
Disease Interactions | |||
First Approval Date | |||
April 17, 2020 |
N/A |
N/A |
|
WADA Class View World Anti-Doping Agency classifications. | |||
N/A |
N/A |
N/A |
|
More Information | |||
Patient resources | |||
Professional Resources | |||
Related Treatment Guide | |||
|
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.